TY - JOUR
T1 - Vestibular Schwannoma International Study of Active Surveillance Versus Stereotactic Radiosurgery
T2 - The VISAS Study
AU - Bin-Alamer, Othman
AU - Abou-Al-Shaar, Hussam
AU - Peker, Selcuk
AU - Samanci, Yavuz
AU - Pelcher, Isabelle
AU - Begley, Sabrina
AU - Goenka, Anuj
AU - Schulder, Michael
AU - Tourigny, Jean Nicolas
AU - Mathieu, David
AU - Hamel, Andréanne
AU - Briggs, Robert G.
AU - Yu, Cheng
AU - Zada, Gabriel
AU - Giannotta, Steven L.
AU - Speckter, Herwin
AU - Palque, Sarai
AU - Tripathi, Manjul
AU - Kumar, Saurabh
AU - Kaur, Rupinder
AU - Kumar, Narendra
AU - Rogowski, Brandon
AU - Shepard, Matthew J.
AU - Johnson, Bryan A.
AU - Trifiletti, Daniel M.
AU - Warnick, Ronald E.
AU - Dayawansa, Samantha
AU - Mashiach, Elad
AU - Vasconcellos, Fernando De Nigris
AU - Bernstein, Kenneth
AU - Schnurman, Zane
AU - Alzate, Juan
AU - Kondziolka, Douglas
AU - Sheehan, Jason P.
N1 - Publisher Copyright:
© 2024 Elsevier Inc.
PY - 2024/10/1
Y1 - 2024/10/1
N2 - Purpose: The present study assesses the safety and efficacy of stereotactic radiosurgery (SRS) versus observation for Koos grade 1 and 2 vestibular schwannoma (VS), benign tumors affecting hearing and neurological function. Methods and Materials: This multicenter study analyzed data from Koos grade 1 and 2 VS patients managed with SRS (SRS group) or observation (observation group). Propensity score matching balanced patient demographics, tumor volume, and audiometry. Outcomes measured were tumor control, serviceable hearing preservation, and neurological outcomes. Results: In 125 matched patients in each group with a 36-month median follow-up (P = .49), SRS yielded superior 5- and 10-year tumor control rates (99% CI, 97.1%-100%, and 91.9% CI, 79.4%-100%) versus observation (45.8% CI, 36.8%-57.2%, and 22% CI, 13.2%-36.7%; P < .001). Serviceable hearing preservation rates at 5 and 9 years were comparable (SRS 60.4% CI, 49.9%-73%, vs observation 51.4% CI, 41.3%-63.9%, and SRS 27% CI, 14.5%-50.5%, vs observation 30% CI, 17.2%-52.2%; P = .53). SRS were associated with lower odds of tinnitus (OR = 0.39, P = .01), vestibular dysfunction (OR = 0.11, P = .004), and any cranial nerve palsy (OR = 0.36, P = .003), with no change in cranial nerves 5 or 7 (P > .05). Composite endpoints of tumor progression and/or any of the previous outcomes showed significant lower odds associated with SRS compared with observation alone (P < .001). Conclusions: SRS management in matched cohorts of Koos grade 1 and 2 VS patients demonstrated superior tumor control, comparable hearing preservation rates, and significantly lower odds of experiencing neurological deficits. These findings delineate the safety and efficacy of SRS in the management of this patient population.
AB - Purpose: The present study assesses the safety and efficacy of stereotactic radiosurgery (SRS) versus observation for Koos grade 1 and 2 vestibular schwannoma (VS), benign tumors affecting hearing and neurological function. Methods and Materials: This multicenter study analyzed data from Koos grade 1 and 2 VS patients managed with SRS (SRS group) or observation (observation group). Propensity score matching balanced patient demographics, tumor volume, and audiometry. Outcomes measured were tumor control, serviceable hearing preservation, and neurological outcomes. Results: In 125 matched patients in each group with a 36-month median follow-up (P = .49), SRS yielded superior 5- and 10-year tumor control rates (99% CI, 97.1%-100%, and 91.9% CI, 79.4%-100%) versus observation (45.8% CI, 36.8%-57.2%, and 22% CI, 13.2%-36.7%; P < .001). Serviceable hearing preservation rates at 5 and 9 years were comparable (SRS 60.4% CI, 49.9%-73%, vs observation 51.4% CI, 41.3%-63.9%, and SRS 27% CI, 14.5%-50.5%, vs observation 30% CI, 17.2%-52.2%; P = .53). SRS were associated with lower odds of tinnitus (OR = 0.39, P = .01), vestibular dysfunction (OR = 0.11, P = .004), and any cranial nerve palsy (OR = 0.36, P = .003), with no change in cranial nerves 5 or 7 (P > .05). Composite endpoints of tumor progression and/or any of the previous outcomes showed significant lower odds associated with SRS compared with observation alone (P < .001). Conclusions: SRS management in matched cohorts of Koos grade 1 and 2 VS patients demonstrated superior tumor control, comparable hearing preservation rates, and significantly lower odds of experiencing neurological deficits. These findings delineate the safety and efficacy of SRS in the management of this patient population.
UR - http://www.scopus.com/inward/record.url?scp=85192169529&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85192169529&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2024.04.004
DO - 10.1016/j.ijrobp.2024.04.004
M3 - Article
C2 - 38588868
AN - SCOPUS:85192169529
SN - 0360-3016
VL - 120
SP - 454
EP - 464
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 2
ER -